First Tracks Biotherapeutics TRAX
NASDAQ TRAX
$46.56 -0.54 (-1.15%)
At close: Nov 16, 2026 · 4:00 PM EST

First Tracks Biotherapeutics (TRAX) Return on Equity [ROE] (2025 - 2026)

Updated

First Tracks Biotherapeutics (TRAX) recorded Return on Equity [ROE] of -176.11% in Q3 2026, down 58.90 percentage points from -117.21% a year earlier and down 39.08 percentage points from the prior quarter.

Analysis

First Tracks Biotherapeutics (TRAX) Return on Equity [ROE] (2025 - 2026) Analysis & Trends

For FY2025, First Tracks Biotherapeutics reported Return on Equity [ROE] of -49.01%.

  • Per Business Quant, the preceding three quarters came in at -137.03% (Q2 2026), -110.63% (Q1 2026) and -114.87% (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 74.39%
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 19.33%
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn -
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 5.63%
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 21.60%
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 72.13%
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -31.17%
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 4.66%
10 First Tracks Biotherapeutics 1.66 Bn 740.14 Mn - -176.11%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -176.11%
Jun 30, 2026 -137.03%
Mar 31, 2026 -110.63%
Dec 31, 2025 -114.87%
Sep 30, 2025 -117.21%
API Access

First Tracks Biotherapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=TRAX&period=max&api_key=YOUR_API_KEY